Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term [Yahoo! Finance]
Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock [Yahoo! Finance]
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $68.00 price target on the stock.
HALO vs. FOLD: Which Stock Should Value Investors Buy Now? [Yahoo! Finance]